References
Mitelman F, Johansson B, Mertens F (eds). Mitelman database of chromosome aberrations in cancer, 2004. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–743.
Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C et al. Imatinib improves but may not fully reverse the poor prognosis of CML patients with derivative chromosome 9 deletions. Blood 2003; 102: 2205–2212.
Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 1998; 352: 1087–1092.
Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738.
Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588.
Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP . Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003; 121: 419–427.
Kolomietz E, Marrano P, Yee K, Thai B, Braude I, Kolomietz A et al. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia 2003; 17: 1313–1323.
Acknowledgements
We thank Drs Sanna Siitonen and Kirsi Autio for assistance with patient samples, Dr Johan Lundin for statistical analysis assistance and Sanna Vesala for dedicated patient record care. This work was supported by grants from the Finnish Medical Research Fund, the Finnish Cancer Society, Signe and Ane Gyllenberg Foundation, Cancer Society of Northern Finland, The Research Fund for Blood Diseases and Helsinki and Oulu University Hospital research funds.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lundán, T., Volin, L., Ruutu, T. et al. Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9. Leukemia 19, 138–140 (2005). https://doi.org/10.1038/sj.leu.2403570
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403570
- Springer Nature Limited